The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Dava Oncology; Dendreon; EMD Serono; Janssen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Neon Therapeutics (Inst); Roche/Genentech (Inst); Seattle Genetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
Matthew I. Milowsky
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seattle Genetics
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seattle Genetics (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Seattle Genetics
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seattle Genetics
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seattle Genetics; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
Christopher J. Hoimes
Honoraria - Seattle Genetics
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seattle Genetics
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seattle Genetics
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seattle Genetics
Elizabeth Henry
Research Funding - Seagen (Inst)
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seattle Genetics; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics (Inst)
Expert Testimony - Celgene; sanofi
Carolyn Sasse
No Relationships to Disclose
Ritesh S. Kataria
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
Yao Yu
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Anne-Sophie Carret
Employment - Seattle Genetics
Stock and Other Ownership Interests - Seattle Genetics
Honoraria - Seattle Genetics
Travel, Accommodations, Expenses - Seattle Genetics
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Adicet Bio; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Fortress Biotech; GlaxoSmithKline; Immunomedics; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seattle Genetics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seattle Genetics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)